Cough, Cold and Allergy (Hay Fever) Remedies in Australia
Whilst the ban on OTC sales of codeine, due to come into effect from February 2018, will hit analgesics the hardest, the ban is also expected to impact growth in cough, cold and allergy remedies over the forecast period, with manufacturers including codeine in certain combination products. In December 2016, Australia’s drug regulator, the Therapeutic Goods Administration (TGA), shifted painkillers containing codeine from schedule two or schedule three to schedule four starting from February 2018...
Euromonitor International's Cough, Cold and Allergy (Hay Fever) Remedies in Australia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2012-2016, allowing you to identify the sectors driving growth. Forecasts to 2021 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market;
Pinpoint growth sectors and identify factors driving change;
Understand the competitive environment, the market’s major players and leading brands;
Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.